CPX-351 Plus Enasidenib for Relapsed AML
Clinical trial NCT03825796 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03825796
- Sponsor
- Jonsson Comprehensive Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-04-12
- Primary completion
- 2024-09-01
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.